HEADER SIGNALING PROTEIN 08-FEB-21 7NG7 TITLE SRC KINASE BOUND TO ECF506 TRAPPED IN INACTIVE CONFORMATION COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: PROTO-ONCOGENE C-SRC,PP60C-SRC,P60-SRC; COMPND 5 EC: 2.7.10.2; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: ECF506 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: SRC, SRC1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS SRC KINASE, INHIBITOR COMPLEX, INACTIVE KINASE, SIGNALING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR D.LIETHA,A.UNCITI-BROCETA REVDAT 4 31-JAN-24 7NG7 1 REMARK REVDAT 3 10-NOV-21 7NG7 1 JRNL REVDAT 2 29-SEP-21 7NG7 1 JRNL REVDAT 1 15-SEP-21 7NG7 0 JRNL AUTH C.TEMPS,D.LIETHA,E.R.WEBB,X.F.LI,J.C.DAWSON,M.MUIR, JRNL AUTH 2 K.G.MACLEOD,T.VALERO,A.F.MUNRO,R.CONTRERAS-MONTOYA, JRNL AUTH 3 J.R.LUQUE-ORTEGA,C.FRASER,H.BEETHAM,C.SCHOENHERR,M.LOPALCO, JRNL AUTH 4 M.J.ARENDS,M.C.FRAME,B.Z.QIAN,V.G.BRUNTON,N.O.CARRAGHER, JRNL AUTH 5 A.UNCITI-BROCETA JRNL TITL A CONFORMATION SELECTIVE MODE OF INHIBITING SRC IMPROVES JRNL TITL 2 DRUG EFFICACY AND TOLERABILITY. JRNL REF CANCER RES. V. 81 5438 2021 JRNL REFN ESSN 1538-7445 JRNL PMID 34417202 JRNL DOI 10.1158/0008-5472.CAN-21-0613 REMARK 2 REMARK 2 RESOLUTION. 1.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.8.0267 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 41.41 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 3 NUMBER OF REFLECTIONS : 39589 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.182 REMARK 3 R VALUE (WORKING SET) : 0.180 REMARK 3 FREE R VALUE : 0.213 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT : 2192 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.54 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2933 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.52 REMARK 3 BIN R VALUE (WORKING SET) : 0.2700 REMARK 3 BIN FREE R VALUE SET COUNT : 149 REMARK 3 BIN FREE R VALUE : 0.3010 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2213 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 41 REMARK 3 SOLVENT ATOMS : 223 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 17.63 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.10000 REMARK 3 B22 (A**2) : 0.02000 REMARK 3 B33 (A**2) : -0.11000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.02000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.080 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.082 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.058 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.106 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.962 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.945 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2309 ; 0.010 ; 0.013 REMARK 3 BOND LENGTHS OTHERS (A): 2196 ; 0.004 ; 0.017 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3130 ; 1.613 ; 1.681 REMARK 3 BOND ANGLES OTHERS (DEGREES): 5062 ; 1.497 ; 1.607 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 272 ;11.022 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 123 ;33.949 ;21.870 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 399 ;12.740 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 17 ;22.077 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 284 ; 0.075 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2560 ; 0.008 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 529 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 263 A 342 REMARK 3 ORIGIN FOR THE GROUP (A): -14.4820 -4.6080 2.1620 REMARK 3 T TENSOR REMARK 3 T11: 0.0590 T22: 0.1165 REMARK 3 T33: 0.1453 T12: 0.0302 REMARK 3 T13: 0.0190 T23: 0.0339 REMARK 3 L TENSOR REMARK 3 L11: 0.8900 L22: 1.8681 REMARK 3 L33: 3.1935 L12: 0.5898 REMARK 3 L13: -0.4989 L23: -1.4745 REMARK 3 S TENSOR REMARK 3 S11: -0.0202 S12: -0.1690 S13: -0.2175 REMARK 3 S21: -0.0145 S22: -0.1321 S23: -0.1489 REMARK 3 S31: 0.2354 S32: 0.2243 S33: 0.1523 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 345 A 536 REMARK 3 ORIGIN FOR THE GROUP (A): -10.4220 3.3120 -21.5560 REMARK 3 T TENSOR REMARK 3 T11: 0.0020 T22: 0.0344 REMARK 3 T33: 0.1137 T12: -0.0047 REMARK 3 T13: 0.0116 T23: -0.0021 REMARK 3 L TENSOR REMARK 3 L11: 0.6851 L22: 0.6084 REMARK 3 L33: 0.5758 L12: -0.1342 REMARK 3 L13: 0.0184 L23: 0.0152 REMARK 3 S TENSOR REMARK 3 S11: -0.0052 S12: -0.0138 S13: -0.0159 REMARK 3 S21: 0.0020 S22: 0.0175 S23: -0.0269 REMARK 3 S31: 0.0041 S32: 0.0249 S33: -0.0122 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS U VALUES : WITH TLS ADDED REMARK 4 REMARK 4 7NG7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 10-FEB-21. REMARK 100 THE DEPOSITION ID IS D_1292113888. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 04-FEB-18 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALBA REMARK 200 BEAMLINE : XALOC REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97912 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41802 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.500 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.06700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.54 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.76300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 4MXO REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.51 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 6% PEG3350, 300MM AMMONIUM ACETATE, REMARK 280 0.1M HEPES PH7.5, 10MM TCEP, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 31.29700 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 220 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13480 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 4.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 250 REMARK 465 SER A 251 REMARK 465 ASP A 252 REMARK 465 ILE A 253 REMARK 465 GLN A 254 REMARK 465 THR A 255 REMARK 465 GLN A 256 REMARK 465 GLY A 257 REMARK 465 LEU A 258 REMARK 465 ALA A 259 REMARK 465 GLY A 424 REMARK 465 ALA A 425 REMARK 465 LYS A 426 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 793 O HOH A 862 1.93 REMARK 500 O HOH A 718 O HOH A 763 1.99 REMARK 500 O HOH A 738 O HOH A 902 2.05 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 388 -15.35 85.81 REMARK 500 ASP A 389 57.54 -146.54 REMARK 500 GLU A 489 -0.63 65.71 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 VAL A 332 SER A 333 -145.37 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue UCW A 602 DBREF 7NG7 A 254 536 UNP P12931 SRC_HUMAN 254 536 SEQADV 7NG7 GLY A 250 UNP P12931 EXPRESSION TAG SEQADV 7NG7 SER A 251 UNP P12931 EXPRESSION TAG SEQADV 7NG7 ASP A 252 UNP P12931 EXPRESSION TAG SEQADV 7NG7 ILE A 253 UNP P12931 EXPRESSION TAG SEQRES 1 A 287 GLY SER ASP ILE GLN THR GLN GLY LEU ALA LYS ASP ALA SEQRES 2 A 287 TRP GLU ILE PRO ARG GLU SER LEU ARG LEU GLU VAL LYS SEQRES 3 A 287 LEU GLY GLN GLY CYS PHE GLY GLU VAL TRP MET GLY THR SEQRES 4 A 287 TRP ASN GLY THR THR ARG VAL ALA ILE LYS THR LEU LYS SEQRES 5 A 287 PRO GLY THR MET SER PRO GLU ALA PHE LEU GLN GLU ALA SEQRES 6 A 287 GLN VAL MET LYS LYS LEU ARG HIS GLU LYS LEU VAL GLN SEQRES 7 A 287 LEU TYR ALA VAL VAL SER GLU GLU PRO ILE TYR ILE VAL SEQRES 8 A 287 THR GLU TYR MET SER LYS GLY SER LEU LEU ASP PHE LEU SEQRES 9 A 287 LYS GLY GLU THR GLY LYS TYR LEU ARG LEU PRO GLN LEU SEQRES 10 A 287 VAL ASP MET ALA ALA GLN ILE ALA SER GLY MET ALA TYR SEQRES 11 A 287 VAL GLU ARG MET ASN TYR VAL HIS ARG ASP LEU ARG ALA SEQRES 12 A 287 ALA ASN ILE LEU VAL GLY GLU ASN LEU VAL CYS LYS VAL SEQRES 13 A 287 ALA ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU SEQRES 14 A 287 TYR THR ALA ARG GLN GLY ALA LYS PHE PRO ILE LYS TRP SEQRES 15 A 287 THR ALA PRO GLU ALA ALA LEU TYR GLY ARG PHE THR ILE SEQRES 16 A 287 LYS SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU SEQRES 17 A 287 LEU THR THR LYS GLY ARG VAL PRO TYR PRO GLY MET VAL SEQRES 18 A 287 ASN ARG GLU VAL LEU ASP GLN VAL GLU ARG GLY TYR ARG SEQRES 19 A 287 MET PRO CYS PRO PRO GLU CYS PRO GLU SER LEU HIS ASP SEQRES 20 A 287 LEU MET CYS GLN CYS TRP ARG LYS GLU PRO GLU GLU ARG SEQRES 21 A 287 PRO THR PHE GLU TYR LEU GLN ALA PHE LEU GLU ASP TYR SEQRES 22 A 287 PHE THR SER THR GLU PRO GLN TYR GLN PRO GLY GLU ASN SEQRES 23 A 287 LEU HET EDO A 601 4 HET UCW A 602 37 HETNAM EDO 1,2-ETHANEDIOL HETNAM UCW TERT-BUTYL (4-(4-AMINO-1-(2-(4-(DIMETHYLAMINO) HETNAM 2 UCW PIPERIDIN-1-YL)ETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3- HETNAM 3 UCW YL)-2-METHOXYPHENYL)CARBAMATE HETSYN EDO ETHYLENE GLYCOL HETSYN UCW ~{TERT}-BUTYL ~{N}-[4-[4-AZANYL-1-[2-[4- HETSYN 2 UCW (DIMETHYLAMINO)PIPERIDIN-1-YL]ETHYL]PYRAZOLO[3,4- HETSYN 3 UCW D]PYRIMIDIN-3-YL]-2-METHOXY-PHENYL]CARBAMATE FORMUL 2 EDO C2 H6 O2 FORMUL 3 UCW C26 H38 N8 O3 FORMUL 4 HOH *223(H2 O) HELIX 1 AA1 PRO A 266 GLU A 268 5 3 HELIX 2 AA2 SER A 306 LYS A 319 1 14 HELIX 3 AA3 SER A 348 GLY A 355 1 8 HELIX 4 AA4 THR A 357 LEU A 361 5 5 HELIX 5 AA5 ARG A 362 MET A 383 1 22 HELIX 6 AA6 ARG A 391 ALA A 393 5 3 HELIX 7 AA7 GLU A 399 LEU A 401 5 3 HELIX 8 AA8 GLY A 409 LEU A 413 5 5 HELIX 9 AA9 TYR A 419 GLN A 423 5 5 HELIX 10 AB1 PRO A 428 THR A 432 5 5 HELIX 11 AB2 ALA A 433 GLY A 440 1 8 HELIX 12 AB3 THR A 443 THR A 460 1 18 HELIX 13 AB4 VAL A 470 ARG A 480 1 11 HELIX 14 AB5 PRO A 491 TRP A 502 1 12 HELIX 15 AB6 GLU A 505 ARG A 509 5 5 HELIX 16 AB7 THR A 511 ASP A 521 1 11 HELIX 17 AB8 ASP A 521 THR A 526 1 6 SHEET 1 AA1 5 LEU A 270 GLN A 278 0 SHEET 2 AA1 5 GLU A 283 TRP A 289 -1 O MET A 286 N VAL A 274 SHEET 3 AA1 5 THR A 293 THR A 299 -1 O THR A 293 N TRP A 289 SHEET 4 AA1 5 TYR A 338 THR A 341 -1 O ILE A 339 N LYS A 298 SHEET 5 AA1 5 LEU A 328 VAL A 332 -1 N TYR A 329 O VAL A 340 SHEET 1 AA2 2 ILE A 395 VAL A 397 0 SHEET 2 AA2 2 CYS A 403 VAL A 405 -1 O LYS A 404 N LEU A 396 CISPEP 1 GLU A 335 PRO A 336 0 -4.93 SITE 1 AC1 6 ILE A 429 THR A 432 PRO A 434 ALA A 437 SITE 2 AC1 6 VAL A 474 HOH A 744 SITE 1 AC2 14 LEU A 276 ALA A 296 LYS A 298 ILE A 339 SITE 2 AC2 14 THR A 341 GLU A 342 MET A 344 GLY A 347 SITE 3 AC2 14 ASP A 351 LEU A 396 ASP A 407 PHE A 408 SITE 4 AC2 14 HOH A 822 HOH A 844 CRYST1 41.778 62.594 51.442 90.00 98.00 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023936 0.000000 0.003364 0.00000 SCALE2 0.000000 0.015976 0.000000 0.00000 SCALE3 0.000000 0.000000 0.019630 0.00000